Brian M. Slomovitz, MD

Articles

ENGOT-EN20/GOG-3083/XPORT-EC-042 – A Phase III, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced, or Recurrent Endometrial Carcinoma: Rationale, Methods, and Trial Design

May 21st 2024

Brian Slomovitz, MD, MS, FACOG, presents the study design, rationale, and primary endpoints of ENGOT-EN20/GOG-3083/XPORT-EC-042, which will be evaluating the efficacy of selinexor compared with placebo as maintenance therapy in patients with advanced or recurrent TP53wt endometrial cancer.

Dr Slomovitz on the DUO-E and AtTEnd Trials Investigating Immunotherapy in Endometrial Cancer

November 9th 2023

Brian M. Slomovitz, MD, discusses the phase 3 DUO-E and AtTEnd trials investigating the use immunotherapy in endometrial cancer, as presented at the 2023 ESMO Congress.

innovaTV 301/ENGOT-cx12/GOG-3057: A Global, Randomized, Open-Label, Phase 3 Study of Tisotumab Vedotin vs Investigator’s Choice of Chemotherapy in 2L or 3L Recurrent or Metastatic Cervical Cancer

October 31st 2023

Brian Slomovitz, MD, provides a look at an upcoming Rapid Readout program looking at the results of a phase 3 study of tisotumab vedotin in patients with recurrent or metastatic cervical cancer.

Dr Slomovitz on the Current Role of PARP Inhibitors in Ovarian Cancer

October 12th 2023

Brian M. Slomovitz, MD, discusses the optimal role for PARP inhibition in patients with ovarian cancer, highlighting its efficacy in those harboring BRCA mutations.

Dr Slomovitz on the Classification of Molecular Subtypes to Guide Treatment in Endometrial Cancer

April 13th 2023

Brian M. Slomovitz, MD, discusses the classification of molecular subtypes to guide treatment and care in endometrial cancers.

Dr Slomovitz on the Investigation of Letrozole Plus Ribociclib in Low-Grade Serous Ovarian Carcinoma

March 28th 2023

Brian M. Slomovitz, MD, discusses the evaluation of letrozole and ribociclib from the phase 2 GOG 3026 trial in recurrent low-grade serous ovarian carcinoma.

Dr. Slomovitz on Sequencing Strategies for Endometrial Cancer

June 16th 2020

Brian M. Slomovitz, MD, discusses sequencing strategies for endometrial cancer.

Dr. Slomovitz on the Importance of Developing Sequencing Strategies in Endometrial Cancer

June 15th 2020

Brian M. Slomovitz, MD, discusses the importance of developing sequencing strategies in endometrial cancer treatment.

Dr. Slomovitz on Sequencing Strategies in Endometrial Cancer

May 2nd 2020

Brian M. Slomovitz, MD, discusses sequencing strategies in endometrial cancer.